OAKLAND, Calif.--(BUSINESS WIRE)--
Girard Gibbs LLP is investigating claims on behalf of investors of Geron Corporation (NASDAQ:GERN) involving possible securities law violations. Specifically, our investigation focuses on allegations that Geron may have issued materially misleading business information to the investing public.
To speak privately with an attorney regarding this class action lawsuit investigation, click here.
On March 27, 2018, STAT, a news organization focused on medical industry reporting, published an article alleging that Geron’s recent stock gains were due to “flimsy” claims regarding the efficacy of Imetelstat, Geron’s experimental treatment for myelofibrosis. The report further states that available data for Imetelstat does not support Geron’s representations about the drug’s efficacy.
Following the publication of the STAT article on March 27, 2018, shares of Geron dropped by more than 13% to close at $5.15 per share. The stock continued to plummet into the next day of trading, closing down 17.86% on March 28, 2018, and causing significant harm to investors.
If you purchased or acquired shares of Geron Corporation and would like to speak privately with a securities attorney to learn more about the investigation and your legal rights, visit our website or contact the securities team directly at (800) 254-9493.
Girard Gibbs LLP is one of the nation’s leading firms representing individual and institutional investors in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and has earned Tier-1 rankings and been named in the U.S. Lawyers – Best Law Firms list for five consecutive years.
This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180328006215/en/
